-- 根據週三提交給澳洲證券交易所的文件顯示，Racura Oncology（ASX：RAC）和伍倫貢大學已獲得新南威爾斯州政府「科技券」（TechVouchers）計畫的資助，用於研究(E,E)-比蒽醌對某些類型乳腺癌和卵巢癌的療效。 文件顯示，Racura與伍倫貢大學的合作旨在為RC220作為一種新型標靶療法的開發提供臨床前證據。 該合作項目的研究結果預計將在未來12個月內公佈。 Racura Oncology的股價在周三的交易中上漲了2%。
Related Articles
Asia
PCL Technologies Incurs NT$94 Million Loss in Q1
PCL Technologies (TPE:4977) posted a loss attributable to owners of NT$94.1 million, or NT$1.18 per basic share, for the first quarter, according to a Tuesday Taiwan bourse filing.The company did not provide comparative year-ago figures.Operating revenue accumulated stood at NT$208.3 million, the optical and electro-mechanical components manufacturer said.
$TPE:4977
Asia
CapitaLand Integrated Commercial Trust Issues 326.1 Million New Units
CapitaLand Integrated Commercial Trust (SGX:C38U) issued 326.1 million units at SG$2.30 per unit via a private placement, according to a Wednesday filing with the Singapore Exchange.Trading in the new units commenced on the same day, the filing added.
$SGX:C38U
Asia
Garden Reach Shipbuilders & Engineers Clocks Gains in Fiscal Q4 Profit; Shares Jump 11%
Garden Reach Shipbuilders & Engineers (NSE:GRSE, BOM:542011) recorded a rise in its profit to 3.03 billion Indian rupees in the fiscal fourth quarter against 2.44 billion rupees a year ago, according to a Tuesday filing to the Indian stock exchanges by the shipbuilder.Shares of the company jumped nearly 11% in recent trade.Earnings per share climbed to 26.47 rupees compared with a year-ago figure of 21.32 rupees.Revenue from operations in fiscal Q4 also increased to 21.2 billion rupees from 16.4 billion rupees a year earlier.The company's board also declared a final dividend of 6.70 rupees per share for the financial year 2025-26.
$BOM:542011$NSE:GRSE